Tobramycin eye drops launched

Tobravisc (tobramycin) eye drops have been launched by Alcon for the treatment of superficial ophthalmic bacterial infections.

Tobramycin is an aminoglycoside antibiotic. It exerts its antibacterial effects by inhibiting bacterial protein assembly and synthesis on the ribosome.

Commonly susceptible organisms include the aerobic Gram-positive bacteria Bacillus megaterium, B. pumilus, Corynebacterium accolens, C. bovis, C. macginleyi, C. pseudodiphtheriticum, Kocuria kristinae, Staphylococcus aureus (methicillin susceptible), S. haemolyticus (methicillin susceptible) and the aerobic Gram-negative bacteria Acinetobacter junii, A. ursingii, Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, K. pneumoniae, Moraxella catarrhalis, M. oslonensis, Morganella morganii, Neisseria perflava, Proteus mirabilis, Pseudomonas aeruginosa and Serratia liquifaciens.

View Tobravisc drug record

Further information: Alcon

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more